Omeros (OMER) Other Non-Current Liabilities (2021 - 2026)
Omeros (OMER) reported Other Non-Current Liabilities of $84.0 million for Q1 2026, up 1766.81% on a YoY basis from $4.5 million in Q1 2025, and down 46.54% sequentially from $157.2 million in Q4 2025.
Omeros (OMER) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Omeros (OMER) has 6 years of Other Non-Current Liabilities data on file, last reported at $84.0 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities rose 1766.81% year-over-year to $84.0 million; the trailing twelve-month figure through Mar 2026 stood at $84.0 million (up 1766.81% YoY), and the FY2025 full-year result was $157.2 million, up 3391.91% from the prior year.
- Other Non-Current Liabilities retreated to $84.0 million in Q1 2026, from $157.2 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $157.2 million in Q4 2025 to a low of $444000.0 in Q4 2022.
- A 5-year average of $17.1 million and a median of $2.1 million in 2023 frame the typical range for Other Non-Current Liabilities.
- Across the five-year window, Other Non-Current Liabilities slumped 60.18% in 2022 and soared 3391.91% in 2025, its largest moves.
- Tracing OMER's Other Non-Current Liabilities over 5 years: stood at $444000.0 in 2022, then surged by 370.27% to $2.1 million in 2023, then surged by 115.57% to $4.5 million in 2024, then soared by 3391.91% to $157.2 million in 2025, then slumped by 46.54% to $84.0 million in 2026.
- Business Quant data shows OMER's Other Non-Current Liabilities at $84.0 million in Q1 2026, $157.2 million in Q4 2025, and $4.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Omeros | 739.31 Mn | 739.31 Mn | 9.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 84.03 Mn |
| Dec 31, 2025 | 157.17 Mn |
| Sep 30, 2025 | 4.50 Mn |
| Jun 30, 2025 | 4.50 Mn |
| Mar 31, 2025 | 4.50 Mn |
| Dec 31, 2024 | 4.50 Mn |
| Sep 30, 2024 | 3.09 Mn |
| Jun 30, 2024 | 2.09 Mn |
| Mar 31, 2024 | 2.09 Mn |
| Dec 31, 2023 | 2.09 Mn |
| Jun 30, 2023 | 496,000.00 |
| Mar 31, 2023 | 452,000.00 |
| Dec 31, 2022 | 444,000.00 |
| Sep 30, 2022 | 999,000.00 |
| Jun 30, 2022 | 961,000.00 |
| Mar 31, 2022 | 922,000.00 |
| Dec 31, 2021 | 1.12 Mn |